For Alkermes' Vivitrol, FDA Not Viewing Trial Results From Russia With Love
This article was originally published in The Pink Sheet Daily
Executive Summary
Underreporting of adverse events may be a Russian "cultural norm," the agency says in a briefing document released in advance of an advisory panel review of Alkermes' Vivitrol (naltrexone) for opioid dependence.
You may also be interested in...
Opioid Addiction Indication Could Offer Fix For Alkermes' Troubled Vivitrol
Alkermes' four-year-old Vivitrol has been struggling to get its head above water as a therapy for alcoholism. But fast-track status for a new opioid addiction indication and a slew of supportive studies at the American Psychiatric Association meeting offer the $900-a-month injectable a shot at recovery
Alkermes To Fly Solo On Vivitrol After Cephalon’s Departure
Biotech cites need to educate physicians about long-acting injectable for alcohol dependence.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.